NONINTERVENTIONAL EXTENSION STUDY FOR PATIENTS TREATED IN STUDY

Recruiting

99 years or below

All

Phase N/A

3 participants needed

1 Location

Brief description of study

The primary objective of the study is to assess adverse events (AEs) and serious adverse events (SAEs) in kidney transplant recipients previously treated with REGN5459 or REGN5458 in the R5459-RT-1944 study. The primary endpoint for this study is the incidence of AEs and SAEs over a 12-month period, starting at the time of kidney transplantation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Kidney transplant recipient enrolled in research study R5459-RT-1944 and received investigational product treatment.

Updated on 04 Aug 2024. Study ID: 851581

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

NONINTERVENTIONAL EXTENSION STUDY FOR PATIENTS TREATED IN STUDY R5459-RT-1944 WITH REGN5459 OR REGN5458 (BCMA CD3 BISPECIFIC ANTIBODIES) WHO RECEIVE A KIDNEY TRANSPLANT

Brief description of study

Eligibility of study

Find a site

Interested in the study